Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Operating Expenses: 2014-2025

Historic Operating Expenses for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $87.7 million.

  • ImmunityBio's Operating Expenses rose 1.54% to $87.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.3 million, marking a year-over-year decrease of 6.59%. This contributed to the annual value of $358.9 million for FY2024, which is 1.09% down from last year.
  • Per ImmunityBio's latest filing, its Operating Expenses stood at $87.7 million for Q3 2025, which was down 10.25% from $97.7 million recorded in Q2 2025.
  • ImmunityBio's 5-year Operating Expenses high stood at $111.9 million for Q1 2023, and its period low was $77.0 million during Q4 2024.
  • In the last 3 years, ImmunityBio's Operating Expenses had a median value of $86.4 million in 2024 and averaged $89.8 million.
  • As far as peak fluctuations go, ImmunityBio's Operating Expenses soared by 157.75% in 2021, and later fell by 15.00% in 2025.
  • ImmunityBio's Operating Expenses (Quarterly) stood at $79.7 million in 2021, then climbed by 6.66% to $85.0 million in 2022, then grew by 0.65% to $85.5 million in 2023, then fell by 10.03% to $77.0 million in 2024, then climbed by 1.54% to $87.7 million in 2025.
  • Its Operating Expenses stands at $87.7 million for Q3 2025, versus $97.7 million for Q2 2025 and $80.9 million for Q1 2025.